Phase 2 trial in 66 adults with M. abscessus lung disease: 84 days of oral omadacycline vs placebo gave symptom response in 34.1% vs 20.0% (definition 1) and 34.1% vs 12.0% (definition 2). 9.8% stopped omadacycline for adverse events, mainly nausea.
RCTn = 66
Winthrop et al. Omadacycline Monotherapy in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus: Results From a Phase 2, Double-blind, Randomized, Placebo-controlled Study